DCGI
Moderna COVID-19 Vaccine in India Soon as Cipla Gets DCGI Nod to Import Vaccine for Restricted Emergency Use: Sources
Cipla Gets DCGI Nod to Import Moderna's COVID-19 Vaccine for Restricted Emergency Use in India, Say Sources
Bharat Biotech’s COVID-19 Vaccine COVAXIN Shows 77.8% Efficacy in Phase III Trials, Say Sources
PETA Urges DCGI to Replace Newborn Calf Serum Method for COVID-19 Vaccine 'Covaxin' Production
Serum Institute of India Gets DCGI's Nod to Manufacture COVID-19 Vaccine Sputnik V in India
COVID-19 Vaccine Update: India Eases Norms for Clearing Foreign-Made Vaccines, Permits Emergency Use Of FDA Approved And WHO Listed Jabs
COVID-19 Vaccine Update: DCGI Allows Emergency Use Of FDA Approved and WHO Listed Vaccines In India
COVID-19 Treatment: Eli Lilly Gets DCGI Emergency-Use Approval for Monoclonal Antibody Drugs Bamlanivimab 700 Mg and Etesevimab 1400 Mg
Zydus Cadila Seeks DCGI Nod To Undertake Clinical Trials for Monoclonal Antibodies Cocktail That Can Neutralise COVID-19 Infection
Covaxin Phase II and III Clinical Trials for 2–18 Age Group To Begin in 10–12 Days, Says Niti Aayog Member VK Paul
DRDO-Developed Drug '2-Deoxy-D-Glucose' Gets DCGI Approval for Emergency Use in Moderate to Severe COVID-19 Patients
Google Trends